Fortress Biotech Announces Cellvation’s CEVA101 Granted FDA Regenerative Medicine Advanced Therapy Designation for the Treatment of Traumatic Brain Injury
November 08, 2017 07:30 ET
|
Fortress Biotech, Inc.
Designation to facilitate expedited development and review of CEVA101 for TBI CEVA101 is being developed in partnership with The University of Texas Health Science Center at Houston (UTHealth) NEW...
Fortress Biotech Announces Pricing of Series A Preferred Stock Offering
November 07, 2017 08:30 ET
|
Fortress Biotech, Inc.
NEW YORK, Nov. 07, 2017 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq:FBIO) (“Fortress”), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical...
Fortress Biotech Announces Proposed Public Offering of Series A Preferred Stock
November 01, 2017 09:20 ET
|
Fortress Biotech, Inc.
NEW YORK, Nov. 01, 2017 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq:FBIO) (“Fortress”), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical...
Fortress Biotech Announces Subsidiary Data to Be Presented at 59th American Society of Hematology Annual Meeting
November 01, 2017 09:05 ET
|
Fortress Biotech, Inc.
NEW YORK, Nov. 01, 2017 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) (“Fortress”), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical...
Fortress Biotech to Present at the 19th Annual Rodman & Renshaw Global Investment Conference
September 05, 2017 08:00 ET
|
Fortress Biotech, Inc.
NEW YORK, Sept. 05, 2017 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) (“Fortress”), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel...
Fortress Biotech Forms New Subsidiary, Aevitas Therapeutics, Inc., to Develop Novel AAV Gene Therapy Treatments for Complement-Mediated Diseases
August 14, 2017 08:00 ET
|
Fortress Biotech, Inc.
NEW YORK, Aug. 14, 2017 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq:FBIO) today announced the formation of a new subsidiary company, Aevitas Therapeutics, Inc. (“Aevitas”), to develop novel...
Fortress Biotech Reports Second Quarter 2017 Financial Results and Recent Corporate Highlights
August 09, 2017 16:05 ET
|
Fortress Biotech, Inc.
NEW YORK, Aug. 09, 2017 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) (“Fortress”), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical...
Fortress Biotech Announces Filing of Provisional Patent Application for Caelum Biosciences’ CAEL-101
July 17, 2017 08:00 ET
|
Fortress Biotech, Inc.
NEW YORK, July 17, 2017 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) (“Fortress”), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical...
Fortress Biotech Announces Appointment of Lucy Lu, MD, as President and Chief Executive Officer of Subsidiary Avenue Therapeutics
July 03, 2017 08:00 ET
|
Fortress Biotech, Inc.
NEW YORK, July 03, 2017 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) (“Fortress”), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical...
Fortress Biotech to Present at the 2017 BIO International Convention
June 15, 2017 08:00 ET
|
Fortress Biotech, Inc.
NEW YORK, June 15, 2017 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) (“Fortress”), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical...